REFERENCE · Fund AI OS archive · not the live product← Back to The Queryable Company
§ 03 ── SEGMENTS ── OVERVIEW

Methodology is segment-specific.
So is the substrate.

Specialist funds compound when methodology survives scale. The Generic Architecture (L0 + L1 Fund AI OS) is the same across VC segments. The overlay (L2) — and the segment-specific patterns it realizes — is what makes each segment work.

§ 03.1 ── RATIONALE

One architecture. Many overlays.

The architecture — eleven agents, audit chain, L8 floors, consent gateways, 4-stage progression, 4-tier framework — is fund-agnostic. It works for an Article 9 impact fund the same way it works for a climate or healthtech fund. What changes is the overlay — the YAML file that loads your specific methodology at bootstrap.

Each segment has its own scoring frameworks, evidence-base integrations, regulatory posture, LP composition, and founder-relationship patterns. Building one overlay teaches us what the next overlay needs. Segments compound; they don't fragment.

FUND OPERATING SUBSTRATEIMPACTL2 · liveCLIMATEL2 · in devHEALTHTECHL2 · in devL2 · SEGMENT-SPECIFICL1 · FUND AI OSeleven agents · audit chain · L8 floors · consent gatewaysL1 · FUND-AGNOSTICL0 · DOCTRINEuniversal — methodology preservation under probabilistic computationL0 · UNIVERSALone architecture · many overlays

FIG. 01 ── L0 DOCTRINE · L1 FRAMEWORK · L2 OVERLAYS → ONE OPERATING SUBSTRATE

§ 03.2 ── ACTIVE + IN DEVELOPMENT

Three segments. One live.

SCORINGEVIDENCE BASEREGULATORYLP VOICELIVEIMPACTHexframe-classPubMed · NICEArticle 9 SFDRFour-tier voiceIN DEVCLIMATETRL 1 → 9IPCC · ecoinventCSRD · CBAMDrift trackingIN DEVHEALTHTECHPhase progressionClinicalTrials · FDACMS · AMNOGReimbursementL1 · FUND AI OS — SHARED ACROSS EVERY SEGMENT

FIG. 02 ── SCORING · EVIDENCE · REGULATORY · LP VOICE — PER SEGMENT

§ 03.3 IMPACT / SFDR ARTICLE 9

LIVE

For funds where impact-tied carry meets LP scrutiny.

First production overlay. Hexframe-class scoring. Evidence-base integrations (PubMed · ClinicalTrials · NICE · Cochrane). Impact Advisory Committee workflows. Four-tier LP voice calibration. Article 9 SFDR audit chain by default.

TRL 1 → 9

§ 03.4 CLIMATE / ENERGY TRANSITION

IN DEVELOPMENT

For funds where LCA validity and TRL scoring meet multi-decade regulatory drift.

Overlay in design. IPCC + ecoinvent + GaBi integrations. TRL 1-9 scoring per technology family. Carbon accounting audit chain (PCAF aligned). Regulatory drift tracking (EU CSRD · EU Taxonomy · IRA · CBAM). Looking for first Climate engagement to co-design v1.0.

§ 03.5 HEALTHTECH / BIOTECH

IN DEVELOPMENT

For funds where clinical evidence and regulatory pathway determine outcome.

Overlay in design. ClinicalTrials + PubMed + NICE + FDA pathway tracking. Mechanism-of-action documentation. Reimbursement risk modeling (CMS · AMNOG · HAS). Phase progression analytics. Looking for first Healthtech engagement.

§ 03.6 ── ROADMAP

Building toward.

We don't list segments we haven't designed for. The roadmap below is what we're researching — not what we're selling. If your fund is in one of these areas and you'd consider being a first-engagement reference, tell us.

NOWSOONHORIZON · RESEARCHING · NOT SELLINGIMPACTliveCLIMATEin devHEALTHTECHin devDEEP TECHCONSUMER WELLNESSINFRASTRUCTUREGENERALIST── TIME ── specialists compound · generalists average

FIG. 03 ── ROADMAP HORIZON · NOW · SOON · RESEARCHING

DEEP TECH

Frontier R&D risk · technical moats · hardware patent prosecution.

CONSUMER WELLNESS

Behavioral evidence · k ≥ 8 privacy floors · sentiment proxies.

INFRA- STRUCTURE

Hardware-software hybrid · clinical pathway analogs · regulatory drift.

EARLY-STAGE GENERALIST*

*probably not — generalists don't compound the way specialists do.

§ 03.7 ── PLATFORM

Beyond VC — the platform thesis.

Segments above are VC-internal. The L0 doctrine is broader. The same substrate that powers Fund AI OS generalizes to specialist law firms, research labs, creative agencies, medical practices.

See the wedge-to-expand thesis for how a single specialist architecture compounds outward.

LAWspecialist firmsRESEARCH LABSevidence-base orgsAGENCIEScreative · seniorMEDICALspecialist practiceVCthe wedgeL0 DOCTRINE GENERALIZES

FIG. 04 ── WEDGE OUTWARD · L0 DOCTRINE GENERALIZES

One core. Many overlays.
One substrate.

── FUND AI OS · 2026

§ END ── TALK

If you operate in one of these segments — or believe yours should be next — tell us.